LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Balance Therapeutics is a clinical-stage pharmaceutical company developing therapies to improve the lives of patients with debilitating neurological conditions. The company focuses on areas of high unmet medical need where neurobiological pathways provide a strong rationale for our pharmacological approach. Balance's experienced drug development team is committed to advancing products to deliver life-improving medicines that serve patients and their families. The company's principal areas of focus are sleep disorders and cognitive deficits.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.